Navigating 21 CFR 312: A Comprehensive Guide

Mar 31

21 CFR 312 is a set of regulations and requirements which are provided by the Food and Drug Administration (FDA). It specifies the procedures and processes that have to be followed by the clinical trials in order to get the approval from the FDA. Without following these regulations it is not possible to ensure that the clinical trial conducted is safe and beneficial for the participants.

21 CFR 312 is a federal regulation from the Code of Federal Regulations that details the requirements for Investigational New Drugs (INDs). This portion of the code offers help to drug manufacturers and sponsors on what is needed to get an IND approved by the Food and Drug Administration (FDA). It also covers areas such as preclinical safety testing requirements, the design of clinical trials protocols and data collection.

The regulation begins by defining what investigational new drugs are and how they are different from other pharmaceutical products. It then outlines the rules for the beginning and supervision of clinical trials and the protocols for reporting to the FDA using Form 1571 before even beginning any trial. 21 CFR 312, however, is not without its requirements for sponsors, such as submitting rather detailed information about the proposed clinical trials to the FDA in the form of a protocol, where among other things, information about the study objectives and endpoints, as well as the investigator's responsibilities, qualifications and IRB approval must be provided. In addition, sponsors are required to provide evidence that the subject has been informed of his or her rights, which include the right to safety and the right to withdraw from the study at any time without penalty.

21 CFR 312 is more specific in detailing some of the documents that should be submitted to the FDA in an IND application. It includes an investigator's brochure based on safety data from previous studies with similar compounds or agents; reports of preclinical studies such as toxicity testing; and all the reports from investigators conducting the clinical trial. The rule also provides for clinical trial monitoring and the reporting of all adverse events and serious unexpected adverse events that occur during the course of a trial.

21 CFR 312 is important to provide drug developers and sponsors with the necessary direction on how to create a new drug safely and within the context of acceptable ethical conduct for the protection of human research subjects. Thus, it plays an important role in protecting the public health by helping to ensure that drugs that are to be marketed for public use are relatively safe as a result of having been tested in humans first.

Who Does 21 CFR 312 Affect?

21 CFR 312 is a regulation issued by the U.S. Food and Drug Administration (FDA) that governs the use of investigational new drugs (INDs) in clinical trials. It establishes the responsibilities and requirements for individuals and organizations involved in the development, approval, and administration of experimental drugs. The regulation primarily affects the following groups:

1. Physicians (Investigators)

Physicians who conduct clinical trials under an IND must comply with 21 CFR 312 to ensure the safety and rights of study participants. Their responsibilities include:

Following the approved protocol for the study.
Reporting adverse events and unexpected side effects.
Maintaining accurate records and submitting data to the sponsor and the FDA.
Obtaining informed consent from participants.
Failure to comply with these regulations can result in penalties, including the termination of the clinical trial.

2. Researchers (Clinical Investigators and Study Staff)

Researchers involved in clinical trials must adhere to the scientific and ethical standards outlined in 21 CFR 312. Their role includes:

Ensuring the validity and integrity of the study data.
Conducting research in accordance with Good Clinical Practice (GCP) guidelines.
Protecting participant safety by monitoring drug effects.
Submitting progress reports to sponsors and regulatory authorities.

3. Sponsors (Pharmaceutical Companies, Biotech Firms, or Institutions)

A sponsor is an entity (such as a pharmaceutical company or research institution) that initiates and funds a clinical trial. 21 CFR 312 places several responsibilities on sponsors, including:

Submitting an IND application to the FDA before conducting human trials.
Providing safety and efficacy data for review.
Monitoring compliance with trial protocols and FDA regulations.
Reporting serious adverse events to the FDA.
Sponsors play a crucial role in ensuring that investigational drugs are developed safely and ethically before reaching the market.

4. Institutional Review Boards (IRBs)

IRBs are independent committees that review and oversee clinical trials to protect the rights, safety, and welfare of human participants. Under 21 CFR 312, IRBs are responsible for:

Reviewing and approving research protocols before trials begin.
Ensuring that informed consent is properly obtained from participants.
Monitoring studies for compliance with ethical and regulatory standards.
Suspending or terminating studies if participant safety is at risk.

How Can I Stay Up to Date With 21 CFR 312?

It is important for anyone wishing to conduct clinical trials to be current with 21 CFR 312. The best way to stay up to date is to make it a habit to review the 21 CFR 312 regulations and requirements and any changes or updates made to them. Furthermore, it is recommended that you consult with an expert in 21 CFR 312 on a regular basis to confirm that you are complying with the regulations and to solve any problems that may arise.

Study Guide for 21 CFR 312

1. Overview: 21 CFR 312 is a part of Title 21 of the Code of Federal Regulations (CFR). It specifies the regulations, procedures, and good laboratory practices that must be followed in the conduct of clinical investigations with drugs and medical devices. Such regulations are meant to provide patient safety and protection during such testing.

2. Investigational New Drug Application (IND): Under Subpart A, any new drug for use in a clinical investigation must have an application made for it. The IND is required to include preclinical pharmacology and toxicology as well as other information pertinent to the development of the drug, including proposed clinical testing protocols.

3. Investigator Responsibilities: Under Subpart B, investigators responsible for conducting clinical trials with investigational drugs or devices are required to fulfill certain obligations. These include obtaining informed consent from the subjects, reporting the progress and adverse effects encountered by the subjects during the trial, keeping proper records and informing the IRB and the sponsor about any unexpected problems or serious adverse events that may happen during the trial.

4. Sponsor Responsibilities: Subpart C outlines the obligations of sponsors, who are responsible for conducting or sponsoring clinical trials with investigational drugs or devices. This includes to monitor study sites in order to determine if the sites are in compliance with the standard of care established by the Good Clinical Practice guidelines and to provide investigators with relevant safety information concerning any investigational product that they may be using in their trial.

5. Institutional Review Boards (IRBs): Subpart D provides guidance on IRBs which are the entities that are to ensure that all research involving human subjects is properly conducted and in compliance with the FDA regulations. It includes the fact that all protocols for clinical trials have to be approved by them before the start of the trial and it also requires them to exercise continuous supervision over a study until the end of the trial in order to ensure that the rights of patients are protected during the trial.

6. Termination or Suspension: Subpart E provides for FDA's ability to halt or terminate active investigations in the event that any safety concerns are observed during a trial which may put subjects at safety risk, or where data collected from a trial becomes unreliable or invalid due to violations of protocol or unethical practices by investigators or sponsors involved in an experiment.

Conclusion

21 CFR 312 plays a crucial role in ensuring the safety, integrity, and ethical conduct of clinical trials in the United States. By outlining the requirements for Investigational New Drug (IND) applications, defining the responsibilities of investigators, sponsors, and Institutional Review Boards (IRBs), and enforcing strict compliance measures, this regulation safeguards both research participants and the reliability of trial data. Adhering to 21 CFR 312 is essential for drug developers seeking FDA approval, as it provides a structured framework for conducting clinical investigations. Staying informed about regulatory updates and maintaining compliance with these guidelines is critical for all stakeholders involved in drug research and development.

For professionals looking to deepen their understanding of 21 CFR 312 and clinical research regulations, CCRPS (Certified Clinical Research Professionals Society) offers comprehensive training programs to help ensure compliance and best practices in the field.

Explore Courses for Clinical Research Career

Courses Available:

Frequently Asked Questions (FAQs)

21 CFR 312 is a set of regulations issued by the US Food and Drug Administration (FDA) to establish good clinical practice (GCP) standards for conducting clinical trials. It covers the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical investigations conducted under FDA regulations.
21 CFR 312 covers interventional studies that involve human participants or data from human participants used to determine the safety or effectiveness of a drug product. These studies may include phase I through IV clinical trials for new drug products as well as bioavailability/bioequivalence studies and post-marketing surveillance activities.
All sponsors and investigators who are involved in conducting clinical investigations subject to FDA jurisdiction must comply with 21 CFR 312. This includes all sponsors and investigators who submit an Investigational New Drug application (IND) to the FDA or an Abbreviated New Drug Application (ANDA).
The key requirements outlined in 21 CFR 312 include obtaining informed consent from study participants; providing accurate records; establishing quality assurance procedures; protecting the rights and welfare of study subjects; ensuring appropriate data collection and analyses techniques; evaluating data integrity; maintaining confidentiality of subjects and their information; training personnel involved in the trial on GCP protocols; preparing detailed reports of findings; establishing audit trails; gaining approval from an Institutional Review Board before beginning any trial activity and many more important elements.
By complying with 21 CFR 312, researchers ensure that human subjects are treated ethically during clinical trials. Key ethical considerations that must be met include obtaining informed consent from study participants; protecting patient privacy; minimizing risk to patients participating in trials and ensuring proper oversight throughout the duration of the trial.
A sponsor’s responsibility under 21 CFR 312 includes developing adequate protocols for each investigation, selecting qualified investigators to ensure effective oversight, obtaining informed consent forms from all patients involved in any investigational activities, providing adequate safeguards regarding patient confidentiality, informing participants about potential risks associated with any investigational activities they may be engaged in and ensuring compliance with all applicable laws related to GCP related activities.
An Institutional Review Board (IRB) has a critical role when conducting investigations subject to FDA jurisdiction as outlined in21CFR312. An IRB is responsible for reviewing protocols submitted by sponsors prior to commencing any investigational activity involving human subjects. The IRB also provides ongoing review and monitoring throughout the course of an investigation to ensure continued adherence to all applicable FDA regulations related to GCP standards outlined in 21CFR312.

21 cfr 31221 cfr part 312cfr 21 part 31221 cfr 312.3221 cfr 312.2321 cfr 312.6221 cfr 312.4021 cfr 312.6021 cfr 312.12021 cfr 312 investigator responsibilities21 cfr 312 pdf21 cfr 312 subpart d21 cfr 312.11021 cfr 312.16021 cfr 312.221 cfr 312.2 b21 cfr 312.2 b 121 cfr 312.2021 cfr 312.2121 cfr 312.21 a21 cfr 312.21 b21 cfr 312.2221 cfr 312.23 a 1021 cfr 312.23 a 221 cfr 312.23 a 321 cfr 312.23 a 521 cfr 312.23 a 621 cfr 312.23 a 6 iii b21 cfr 312.23 a 721 cfr 312.23 a 7 iv e21 cfr 312.23 a 821 cfr 312.321 cfr 312.3 b21 cfr 312.3021 cfr 312.30021 cfr 312.30521 cfr 312.3121 cfr 312.31021 cfr 312.31521 cfr 312.32 a21 cfr 312.32 c21 cfr 312.32 c 121 cfr 312.32021 cfr 312.3321 cfr 312.3421 cfr 312.3821 cfr 312.4221 cfr 312.4721 cfr 312.5021 cfr 312.5221 cfr 312.5321 cfr 312.53 c21 cfr 312.5521 cfr 312.5621 cfr 312.5721 cfr 312.5921 cfr 312.621 cfr 312.6121 cfr 312.62 b21 cfr 312.62 c21 cfr 312.6421 cfr 312.64 b21 cfr 312.6621 cfr 312.6821 cfr 312.721 cfr 312.7021 cfr 312.8021 cfr 312.8221 cfr part 312 deals with21 cfr part 312 pdf21 cfr part 312 ppt21 cfr part 312 subpart e21 cfr part 312 summary21 cfr part 312.3221 cfr part 312.6221 cfr part 312.6440 cfr 312.21cfr title 21 part 312fda 21 cfr 312fda 21 cfr 312 are the regulations governingfda 21 cfr 312.32fda 21 cfr part 312title 21 cfr part 31221 cfr part 312.32 provides regulations abouttitle 21 part 312 cfr21 cfr 210.31221 cfr 312 12021 cfr 312 201621 cfr 312 3221 cfr 312 5021 cfr 312 50 responsibilities of sponsors and investigators21 cfr 312 81221 cfr 312 and 81221 cfr 312 annual reports21 cfr 312 deviation21 cfr 312 drug expiration21 cfr 312 handbooks21 cfr 312 human subject protection21 cfr 312 ind exemption21 cfr 312 ind regulations21 cfr 312 investigational new drug21 cfr 312 investigational new drug accountability21 cfr 312 labeling21 cfr 312 monitoring21 cfr 312 nih21 cfr 312 protocol21 cfr 312 protocol amendment21 cfr 312 subpart b21 cfr 312 subpart d pdf21 cfr 312 subpart d pdf format21 cfr 312 subpart d responsibilities of sponsors and investigators21 cfr 312 subpart d selecting investigators and monitors21 cfr 312 subpart e21 cfr 312 subpart e-drugs intended to treat life21 cfr 312 subpart i21 cfr 312 subpbart i21 cfr 312 traing21 cfr 312 training21 cfr 312 vs 21 cfr 81221 cfr 312.10021 cfr 312.120 a 1 i21 cfr 312.120 b 121 cfr 312.120 c 121 cfr 312.120 c 421 cfr 312.120a1i21 cfr 312.120c121 cfr 312.120c421 cfr 312.160 a 1 i21 cfr 312.1721 cfr 312.2 b 1 iii21 cfr 312.2 b 1 iv21 cfr 312.2 b 421 cfr 312.2 b 521 cfr 312.2 b and 320.31 b21 cfr 312.2 b iv21 cfr 312.2 c21 cfr 312.20 b21 cfr 312.20 subpart b ind application21 cfr 312.21 a 121 cfr 312.21 a 1 and 221 cfr 312.21 c21 cfr 312.21 phases of an investigation21 cfr 312.22 a21 cfr 312.22 and 312.2321 cfr 312.22 d21 cfr 312.23 11 b21 cfr 312.23 201921 cfr 312.23 a21 cfr 312.23 a 1 iv21 cfr 312.23 a 1 vi21 cfr 312.23 a 1 vii21 cfr 312.23 a 3 iv21 cfr 312.23 a 5 investigator's brochure21 cfr 312.23 a 6 iii21 cfr 312.23 a 6 iii g21 cfr 312.23 a 7 d21 cfr 312.23 a 7 iii21 cfr 312.23 a 7 iv a21 cfr 312.23 a 7 iv c21 cfr 312.23 a 7 iv d21 cfr 312.23 a 8 ii b21 cfr 312.23 b21 cfr 312.23 cornell21 cfr 312.23 f21 cfr 312.23 ind content and format21 cfr 312.23a21 cfr 312.23a1vi21 cfr 312.23a221 cfr 312.23a321 cfr 312.23a3iv21 cfr 312.23a6iiib.21 cfr 312.23a721 cfr 312.23a7i21 cfr 312.23a7ii21 cfr 312.23a7iv b21 cfr 312.23a7ivb21 cfr 312.23a7ivd21 cfr 312.23a821 cfr 312.23e21 cfr 312.2b121 cfr 312.2b1iv21 cfr 312.3 b and 21 cfr 812.3 i21 cfr 312.30 b 121 cfr 312.30 b 2 ii21 cfr 312.300 b 121 cfr 312.30a21 cfr 312.32 and 312.3321 cfr 312.32 b21 cfr 312.32 c 1 a21 cfr 312.32 c 1 a and b21 cfr 312.32 c 1 b ii21 cfr 312.32 c 1 i21 cfr 312.32 c 1 i a21 cfr 312.32 c 1 ii21 cfr 312.32 c 1 ii and iii21 cfr 312.32 c 1 iii21 cfr 312.32 c 1 iv21 cfr 312.32 c 1 v21 cfr 312.32 c 221 cfr 312.32 c 321 cfr 312.32 c 421 cfr 312.32 c 521 cfr 312.32 d21 cfr 312.32 ind safety reporting21 cfr 312.32 ind safety reports21 cfr 312.32 pdf21 cfr 312.32c1iv21 cfr 312.32c1v21 cfr 312.32c421 cfr 312.32c521 cfr 312.32d21 cfr 312.33 annual reports21 cfr 312.33 b 621 cfr 312.33 b 721 cfr 312.33 d21 cfr 312.33 ind annual report21 cfr 312.34 and 312.3521 cfr 312.34 removal21 cfr 312.4121 cfr 312.42 b 1 ii21 cfr 312.42 b 1 iv21 cfr 312.42 b 2 ii21 cfr 312.521 cfr 312.50 and 312.5621 cfr 312.50 general responsibilities of investigators21 cfr 312.52 b21 cfr 312.52 form21 cfr 312.53 a21 cfr 312.53 c 121 cfr 312.53 c 1 viii21 cfr 312.53 c 221 cfr 312.53 c 421 cfr 312.53 d21 cfr 312.53b21 cfr 312.53c221 cfr 312.53d21 cfr 312.55 b21 cfr 312.57 b21 cfr 312.57 c21 cfr 312.57 d21 cfr 312.57 recordkeeping and record retention21 cfr 312.6 a21 cfr 312.6 labeling of an investigational new drug21 cfr 312.60 general responsibilities of investigators21 cfr 312.61 control of the investigational drug21 cfr 312.62 2121 cfr 312.62 a21 cfr 312.62 and 312.6821 cfr 312.62 and 812.14021 cfr 312.62 b and 812.140 a 321 cfr 312.62 b and 812.140 b21 cfr 312.62b and 812.140a321 cfr 312.64 and 21 cfr 312.3221 cfr 312.64 d21 cfr 312.64 investigator reports21 cfr 312.6921 cfr 312.7 a21 cfr 312.8 d21 cfr 50 56 312 812 fda regulations summary21 cfr 50 56 312 and 81221 cfr part 11 31221 cfr part 312 and 81221 cfr part 312 financial disclosure21 cfr part 312 ind regulations21 cfr part 312 purpose21 cfr part 312 subpart d21 cfr part 312 subpart h21 cfr part 312 subpart i21 cfr part 312 wikipedia21 cfr part 312.11021 cfr part 312.2 b21 cfr part 312.2321 cfr part 312.23 a 721 cfr part 312.321 cfr part 312.3 b21 cfr part 312.3021 cfr part 312.30021 cfr part 312.31021 cfr part 312.3321 cfr part 312.3421 cfr part 312.5021 cfr part 312.5221 cfr part 312.5321 cfr part 312.5521 cfr part 312.55 a21 cfr part 312.5721 cfr part 312.5921 cfr part 312.621 cfr part 312.6021 cfr part 312.62 b21 cfr part 312.62b21 cfr part 312.6621 cfr part 312.6821 cfr part 312.721 cfr part 312.7021 cfr part 312.821 cfr part 312.8221 cfr parts 31221 cfr parts 50 54 56 and 31221 cfr parts 50 56 and 31221 cfr parts 56 312 and 81221 cfr sec 312.53 c21 cfr sec. 312.53c21 cfr section 312 subpart d21 cfr section 312.2121 cfr section 312.2221 cfr section 312.3321 cfr section 312.5021 cfr section 312.5721 cfr section 312.57 c21 cfr section 312.6021 cfr section 312.6221 cfr section 312.6421 cfr section 312.721 cfr section 312.7038 cfr 21.31240 cfr part 312.2140 cfr section 312.21additional information 21 cfr 312.23 a 10cfr 21 312.312cfr 21 312.32cfr 21 312.43cfr title 21 part 312 section 17cfr title 21 part 312. investigational new drug applicationcmc regulation 21 cfr 312.23 a 7 icode of federal regulations 21 cfr 312contraindication 21 cfr 312expanded access use 21 cfr 312.300fda 1572 21 cfr 312.53 cfda 1572 21 cfr 312.53cfda 21 cfr 312 auditfda 21 cfr 312 reporting deviationfda 21 cfr 312 subpart dfda 21 cfr 312.120fda 21 cfr 312.20fda 21 cfr 312.21fda 21 cfr 312.23fda 21 cfr 312.3fda 21 cfr 312.3 bfda 21 cfr 312.30fda 21 cfr 312.300fda 21 cfr 312.310fda 21 cfr 312.32 cfda 21 cfr 312.320fda 21 cfr 312.33fda 21 cfr 312.34fda 21 cfr 312.47fda 21 cfr 312.50fda 21 cfr 312.52fda 21 cfr 312.53fda 21 cfr 312.55fda 21 cfr 312.57fda 21 cfr 312.59fda 21 cfr 312.60fda 21 cfr 312.62fda 21 cfr 312.64fda 21 cfr 312.66fda 21 cfr 312.68fda 21 cfr 312.70fda 21 cfr 312.82fda 21 cfr part 312 investigational new drug applicationfda 21 cfr part 312 pdffda 21 cfr part 312.120fda 21 cfr part 312.32fda 21 cfr part 312.50fda 21 cfr part 312.52fda 21 cfr part 312.53fda 21 cfr part 312.56fda 21 cfr part 312.62fda 21 cfr part 312.68fda cfr title 21 part 312.64fda code of federal regulations 21 cfr part 312.53fda part 21 cfr 312fda regulation 21 cfr 312.59fda regulation 21 cfr 312.62fda regulations at 21 cfr 312.32 afda title 21 cfr part 312fda under 21 cfr 312.23 a 6 iii bfederal regulation 21 cfr 312.62form fda 1572 21 cfr 312.53 cind 21 cfr 312ind under 21 cfr 312.2 b 1individual patients including for emergency use 21 cfr 312.310introductory statement 21 cfr 312.23a3investigational new drug application 21 cfr part 312irb data 21 cfr 312.23per 21 cfr 312.33previous human experience 21 cfr 312.23 a 9promotional item fda submissions 21 cfr 312.32see 21 cfr 312.21asee 21 cfr 312.3 bsee 21 cfr 312.53see 21 cfr 312.62 and 812.140see 21 cfr 312.62 bside effect 21 cfr 312table of contents 21 cfr 312.23 a 2title 21 cfr 312title 21 cfr 312.2 btitle 21 cfr 312.42 ctitle 21 cfr 312.57title 21 cfr 312.59title 21 cfr part 312 1993title 21 cfr part 312.52u.s cfr title 21 parts 50 56 and 312under 21 cfr 312.32under 21 cfr 312.64us 21 cfr 312.120us 21 cfr 312.21us 21 cfr 312.52us 21 cfr 312.64us fda 21 cfr 312.32us fda 21 cfr 312.57us fda title 21 cfr part 312usa 21 cfr 312.120what does 21 cfr 312 coverwhat is 21 cfr 312what is the 21 cfr 312what is the purpose of 21 cfr 312

Brian Achille

Navigating 21 CFR 312: A Comprehensive Guide